# autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) 규제 동향
**

## 핵심 요약

## 글로벌 승인 현황


## 국내 도입 전망


## 메드클레임 시사점


---
*생성: 2026-02-13 13:49 | RegScan AI*